Ocrelizumab Co-formulated With rHuPH20

Phase 3

Ocrelizumab Co-formulated With rHuPH20 is one of 66 therapeutic programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Relapsing-Remitting Multiple SclerosisNot yet recruiting

Multiple SclerosisActive, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 3

Not yet recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Zyrtec

KKenvue Brands

Phase 3

1 4

Vumerity

Biogen

Phase 3

4 5

Frexalimab

Sanofi

Phase 3

2 6

Clemastine Fumarate

Novartis

Phase 3

2 7

Activated Charcoal

Sanofi

Phase 3

1 8

Mayzent

Novartis

Phase 3

1 9

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 10

Ocrelizumab Co-formulated With rHuPH20

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Multiple Sclerosis

NCT07667322

Q3 2031

Phase 3Not yet recruiting

Relapsing-Remitting Multiple Sclerosis

NCT07503340

Clinical

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis1 trial

An Open-label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis

Not yet recruiting· Roche logo

Roche·Phase 3·NCT07503340·25 enrolled

Multiple Sclerosis1 trial

A Phase 1b Multicenter, Non-randomized, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Single Ascending Doses of a New Subcutaneous Formulation of Ocrelizumab in Patients With Multiple Sclerosis

Active, not recruiting· Roche logo

Roche·Phase 1·NCT07667322·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ocrelizumab Co-formulated With rHuPH20. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ocrelizumab Co-formulated With rHuPH20. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Roche

Ocrelizumab Co-formulated With rHuPH20

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2031

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News